Historical source coverage
14 selected records with a cited source date in 2011. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00557310 at 2026-07-30T22:15:58.883Z. Its registry update date was 2011-11-11, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT00797823 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-10-07, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00761332 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-06-21, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Regulatory · Leuprolide
The Federal Register published notice 2011-14164, attributed to FDA and its parent HHS department, on 2011-06-08. Its official title is “Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
Source: Federal Register via GovInfo ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00343252 at 2026-07-30T22:15:58.895Z. Its registry update date was 2011-05-26, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Literature metadata · Lanreotide
PeptideScanner retained PubMed bibliographic metadata for PMID 21607321 at 2026-07-30T22:17:00.088Z. PubMed recorded a metadata revision date of 2011-05-24 and an Entrez history date of 2011-05-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Octreotide
The official Drugs@FDA dataset lists original submission 1 for ANDA 090985 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Octreotide
The official Drugs@FDA dataset lists original submission 1 for ANDA 090986 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00696644 at 2026-07-30T22:15:58.886Z. Its registry update date was 2011-05-09, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00439244 at 2026-07-30T22:15:58.884Z. Its registry update date was 2011-04-20, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT00850564 at 2026-07-30T22:15:58.888Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Literature metadata · Emideltide
PeptideScanner retained PubMed bibliographic metadata for PMID 21262293 at 2026-07-30T22:17:00.064Z. PubMed recorded a metadata revision date of 2011-03-18 and an Entrez history date of 2011-01-26. PeptideScanner associated this retained record with the identity slug emideltide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Bremelanotide
PeptideScanner retained ClinicalTrials.gov record NCT00425256 at 2026-07-30T22:15:58.882Z. Its registry update date was 2011-02-23, and PeptideScanner's reviewed identity mapping was bremelanotide.
Source: ClinicalTrials.gov ↗
Regulatory · Octreotide
The official Drugs@FDA dataset lists original submission 1 for ANDA 079198 with status AP dated 2011-02-10, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗